Meet the Nucleic Acids team
Building a global patent portfolio for antisense therapeutics – Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals is the industry leader in designing and developing RNA-targeting antisense oligonucleotide therapeutics. Carpmaels & Ransford advises Ionis on its global patent portfolio across its large and diverse pipeline. We use our decades of expertise in handling patent applications in multiple jurisdictions to obtain robust worldwide protection for Ionis’ platform technologies and for its therapeutic oligonucleotides. We have also successfully prosecuted and then defended a number of important Ionis patents at the EPO, and advise Ionis on SPC strategy to maximise protection for its approved products.